Vericel Corp (VCEL) Stock AnalysisVCELStock AnalysisVericel Corp

Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vericel Corp is a good buy right now due to its recent strong earnings performance, with Q2 revenue of $77.5 million representing a 22.5% year-over-year increase and an EPS of $0.04, beating expectations by $0.07. The stock is currently priced at $40.95, which is below several analyst price targets, indicating potential upside. However, the RSI is low at 26.008, suggesting that the stock may be oversold, which could present a buying opportunity. The main risk is the forward P/E ratio of 89.2857, indicating high expectations for future growth that may not materialize.

4 analysts cover VCEL: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 57.67.